con edison dsip Invests for Summer 2020 and New York's Clean ConEdison | The Org

Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D et al

BPC-157 is a research-stage compound without the extensive Phase I, II, and III clinical trials that FDA-approved medications undergo

It is important to note that the majority of this mechanistic research has been conducted in cell culture and animal models, with a significant proportion originating from a single research group

Traditional joint supplements Glucosamine, chondroitin, and omega-3 fatty acids (particularly EPA and DHA from fish oil) have real evidence behind them

Across this body of literature the compound has been described under several names: pentadecapeptide BPC-157, the full Body Protection Compound 157, the early trial designation PL 14736, and the proprietary name Bepecin used in early Croatian pharmaceutical work